Journal of Neuro-Oncology

Papers
(The H4-Index of Journal of Neuro-Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Immune suppression in gliomas158
A review of glioblastoma immunotherapy149
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis109
The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature65
Response to trametinib treatment in progressive pediatric low-grade glioma patients64
Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and62
Awake glioma surgery: technical evolution and nuances59
Convection-enhanced drug delivery for glioblastoma: a review50
A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma48
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer48
Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database44
Boron neutron capture therapy for malignant brain tumors44
Intraoperative MRI for Brain Tumors43
Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery42
Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial41
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma41
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor40
Combination immunotherapy strategies for glioblastoma37
Laser interstitial thermotherapy (LITT) for the treatment of tumors of the brain and spine: a brief review37
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience36
Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection36
Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice35
Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review35
High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity33
Neurotoxicities associated with immune checkpoint inhibitor therapy32
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment31
Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review30
Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases30
Minimally invasive resection of intracranial lesions using tubular retractors: a large, multi-surgeon, multi-institutional series29
0.061758041381836